These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 2868608)
1. Changes in mental condition, hyperkinesias and biochemical parameters after withdrawal of chronic neuroleptic treatment. Perényi A; Frecska E; Bagdy G; Révai K Acta Psychiatr Scand; 1985 Nov; 72(5):430-5. PubMed ID: 2868608 [TBL] [Abstract][Full Text] [Related]
2. Decrease in dopamine, its metabolites and noradrenaline in cerebrospinal fluid of schizophrenic patients after withdrawal of long-term neuroleptic treatment. Bagdy G; Perényi A; Frecska E; Révai K; Papp Z; Fekete MI; Arató M Psychopharmacology (Berl); 1985; 85(1):62-4. PubMed ID: 2580329 [TBL] [Abstract][Full Text] [Related]
3. Comparative neurochemical investigation of tardive dyskinesia and neuroleptic-induced chronic parkinsonism. Arató M; Bagdy G; Perényi A; Béla A Psychiatry Res; 1984 Apr; 11(4):347-51. PubMed ID: 6146151 [TBL] [Abstract][Full Text] [Related]
4. Long-term neuroleptic treatment of chronic schizophrenic patients: clinical and biochemical effects of withdrawal. Zander KJ; Fischer B; Zimmer R; Ackenheil M Psychopharmacology (Berl); 1981; 73(1):43-7. PubMed ID: 6112769 [TBL] [Abstract][Full Text] [Related]
5. Neurochemical studies on tardive dyskinesia. I. Urinary homovanillic acid and plasma prolactin. Tripodianakis J; Markianos M; Garelis E Biol Psychiatry; 1983 Mar; 18(3):337-45. PubMed ID: 6132625 [TBL] [Abstract][Full Text] [Related]
7. Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents. Gualtieri CT; Quade D; Hicks RE; Mayo JP; Schroeder SR Am J Psychiatry; 1984 Jan; 141(1):20-3. PubMed ID: 6140865 [TBL] [Abstract][Full Text] [Related]
8. The effect of neuroleptic discontinuation on psychopathology, involuntary movements, and biochemical measures in patients with persistent tardive dyskinesia. Glazer WM; Bowers MB; Charney DS; Heninger GR Biol Psychiatry; 1989 Jul; 26(3):224-33. PubMed ID: 2568132 [TBL] [Abstract][Full Text] [Related]
9. [Psychopathologic changes in chronic schizophrenic patients following withdrawal of neuroleptics: relation to therapeutic, neuroendocrine and computer tomography variables]. Albus M; Naber D; Ackenheil M; Bürke H; Müller-Spahn F; Münch U; Reinertshofer T; Schmidt-Vanderheyden W; Weber G; Wissmann J Fortschr Neurol Psychiatr; 1986 Jan; 54(1):15-20. PubMed ID: 2868983 [TBL] [Abstract][Full Text] [Related]
10. Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures. Gardos G; Cole JO; Rapkin RM; LaBrie RA; Baquelod E; Moore P; Sovner R; Doyle J Arch Gen Psychiatry; 1984 Nov; 41(11):1030-5. PubMed ID: 6149737 [TBL] [Abstract][Full Text] [Related]
11. Multivariate analysis of monoamine indices in patients with chronic schizophrenia. Frecska E; Bagdy G; Perenyi A; Arato M; Degrell I; Mogyorosy Z J Neuropsychiatry Clin Neurosci; 1989; 1(3):291-5. PubMed ID: 2577713 [TBL] [Abstract][Full Text] [Related]
12. Plasma homovanillic acid and tardive dyskinesia during neuroleptic maintenance and withdrawal. Kirch D; Hattox S; Bell J; Murphy R; Freedman R Psychiatry Res; 1983 Jul; 9(3):217-23. PubMed ID: 6137850 [TBL] [Abstract][Full Text] [Related]
13. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation. Davidson M; Kahn RS; Powchik P; Warne P; Losonczy MF; Kaminsky R; Apter S; Jaff S; Davis KL Arch Gen Psychiatry; 1991 Jan; 48(1):73-6. PubMed ID: 1670618 [TBL] [Abstract][Full Text] [Related]
14. Tiapride in the treatment of tardive dyskinesia: a clinical and biochemical study. Perényi A; Arató M; Bagdy G; Frecska E; Szücs R J Clin Psychiatry; 1985 Jun; 46(6):229-31. PubMed ID: 2860098 [TBL] [Abstract][Full Text] [Related]
15. Associations among plasma prolactin levels, tardive dyskinesia, and paranoia in treated schizophrenics: relevance to supersensitivity psychosis. Csernansky JG; Vinogradov S; Prosser E; Kaplan J; Berger PA; Hollister LE Psychopharmacol Bull; 1986; 22(3):897-9. PubMed ID: 2879311 [No Abstract] [Full Text] [Related]
16. Why neuroleptic withdrawal in schizophrenia? Carpenter WT; Tamminga CA Arch Gen Psychiatry; 1995 Mar; 52(3):192-3. PubMed ID: 7872843 [No Abstract] [Full Text] [Related]
17. Neurochemical findings in the cerebrospinal fluid of schizophrenic patients with tardive dyskinesia and neuroleptic-induced parkinsonism. Saito T; Ishizawa H; Tsuchiya F; Ozawa H; Takahata N Jpn J Psychiatry Neurol; 1986 Jun; 40(2):189-94. PubMed ID: 2431183 [TBL] [Abstract][Full Text] [Related]
18. The dopamine-serotonin relationship in clozapine response. Szymanski S; Lieberman J; Pollack S; Munne R; Safferman A; Kane J; Kronig M; Cooper T Psychopharmacology (Berl); 1993; 112(1 Suppl):S85-9. PubMed ID: 7530378 [TBL] [Abstract][Full Text] [Related]
19. Possible associations among plasma prolactin levels, tardive dyskinesia, and paranoia in treated male schizophrenics. Csernansky JG; Prosser E; Kaplan J; Mahler E; Berger PA; Hollister LE Biol Psychiatry; 1986 Jun; 21(7):632-42. PubMed ID: 2871874 [TBL] [Abstract][Full Text] [Related]
20. Changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double-blind design. Dixon L; Thaker G; Conley R; Ross D; Cascella N; Tamminga C Schizophr Res; 1993 Oct; 10(3):267-71. PubMed ID: 8260445 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]